IL317385A - Prevention or mitigation of adverse effects related to recombinant viral vectors - Google Patents

Prevention or mitigation of adverse effects related to recombinant viral vectors

Info

Publication number
IL317385A
IL317385A IL317385A IL31738524A IL317385A IL 317385 A IL317385 A IL 317385A IL 317385 A IL317385 A IL 317385A IL 31738524 A IL31738524 A IL 31738524A IL 317385 A IL317385 A IL 317385A
Authority
IL
Israel
Prior art keywords
mitigation
prevention
adverse effects
viral vectors
recombinant viral
Prior art date
Application number
IL317385A
Other languages
Hebrew (he)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of IL317385A publication Critical patent/IL317385A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0083—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the administration regime
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL317385A 2022-08-15 2023-08-14 Prevention or mitigation of adverse effects related to recombinant viral vectors IL317385A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP22190354 2022-08-15
PCT/EP2023/072361 WO2024038002A1 (en) 2022-08-15 2023-08-14 Prevention or mitigation of adverse effects related to recombinant viral vectors

Publications (1)

Publication Number Publication Date
IL317385A true IL317385A (en) 2025-02-01

Family

ID=83447887

Family Applications (1)

Application Number Title Priority Date Filing Date
IL317385A IL317385A (en) 2022-08-15 2023-08-14 Prevention or mitigation of adverse effects related to recombinant viral vectors

Country Status (11)

Country Link
US (1) US20260000670A1 (en)
EP (1) EP4572793A1 (en)
JP (1) JP2025526697A (en)
KR (1) KR20250050869A (en)
CN (1) CN119730884A (en)
AU (1) AU2023327682A1 (en)
CA (1) CA3264415A1 (en)
IL (1) IL317385A (en)
MX (1) MX2025001461A (en)
TW (1) TW202416993A (en)
WO (1) WO2024038002A1 (en)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
EP3795581A3 (en) 2011-08-24 2021-06-09 The Board of Trustees of the Leland Stanford Junior University New avv capsid proteins for nucleic acid transfer
JP6342886B2 (en) 2012-04-18 2018-06-13 ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィアThe Children’S Hospital Of Philadelphia Composition and method for highly efficient gene transfer using AAV capsid variants
NZ716102A (en) 2013-07-22 2021-12-24 The Children’S Hospital Of Philadelphia Variant aav and compositions, methods and uses for gene transfer to cells, organs and tissues
US11021545B2 (en) * 2018-07-31 2021-06-01 The Regents Of The University Of California Multimodal cancer therapy comprising chimeric viral/nonviral nanoparticles and anticancer agents
US20230277633A1 (en) * 2020-06-05 2023-09-07 Shanghai Bao Pharmaceuticals Co., Ltd. Pharmaceutical composition of enzymes and viruses and application thereof

Also Published As

Publication number Publication date
US20260000670A1 (en) 2026-01-01
EP4572793A1 (en) 2025-06-25
MX2025001461A (en) 2025-03-07
TW202416993A (en) 2024-05-01
CN119730884A (en) 2025-03-28
JP2025526697A (en) 2025-08-15
KR20250050869A (en) 2025-04-15
AU2023327682A1 (en) 2024-12-05
CA3264415A1 (en) 2024-02-22
WO2024038002A1 (en) 2024-02-22

Similar Documents

Publication Publication Date Title
ZA202100202B (en) Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins
IL288419A (en) Recombinant herpesvirales vector
BR112022001912A2 (en) Cellular compositions comprising viral vectors and treatment methods
MA55480A (en) METHODS OF MAKING RECOMBINANT VIRAL VECTORS
IL314658A (en) Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a
IL321162A (en) Adeno-associated viral vectors for proper packaging of repetitive elements
CA3264415A1 (en) Prevention or mitigation of adverse effects related to recombinant viral vectors
IL316348A (en) Prevention or mitigation of t-cell engaging agent-related adverse effects
KR102248420B9 (en) Recombinant vector containing the target sequence of miR-142-3p
ZA202203832B (en) Co-production of high purity isobutane and butene-1 from mixed c4s
CA206918S (en) Set of eye shields
ZA202109060B (en) Stabilization of suspension concentrates by hydrophobic fumed silica
ZA202109011B (en) Stable formulations of recombinant proteins
HUE073273T2 (en) Stabilization of suspension concentrates by ethoxylated ricinolein
GB202312083D0 (en) Viral vector
EP4370698A4 (en) Compositions for and methods of improving viral vectors
EP4588194A4 (en) Suppression of elemental yield outside the range at gamma beams
GB202111753D0 (en) Instruction interrupt suppression of overflow exception
HK40088883A (en) Compositions for preservation of viral vectors
GB202211673D0 (en) Viral vector
GB202510959D0 (en) Improved viral vectors
GB202104320D0 (en) Enhancement of viral titres
EP4507699A4 (en) Chemogenetic regulation of peptide function
HK40103866A (en) Use of cd8-targeted viral vectors
CA222234S (en) Pair of gloves